Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years.~2. Histologically, cytologically, or radiologically confirmed liver dominant or liver only malignancy.~3. Preserved liver function (Child-Pugh A-B class) without significant liver decompensation.~4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 at study entry.~5. Measurable or evaluable disease that will be directly treated with intrahepatic therapy (as defined by Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1).~6. Suitable for TACE based on blood parameters such as platelet count, bilirubin, and international normalized ratio.~7. May be enrolled with a history of prior liver directed intra-arterial therapy if intra-arterial therapy to the target lesion occured \> 1 year prior to enrollment date. Intra-arterial therapy to different targets within 1 year prior to enrollment date will not exclude subjects.~Exclusion Criteria:~1. Serum total bilirubin \> 3.0 mg/dL~2. Creatinine \> 2.0 mg/dL~3. Platelets \< 50000/µL~4. Complete portal vein thrombosis with reversal of flow~5. Ascites (trace ascites on imaging is acceptable)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- whole liver lobe cTACE doxorubicin (Type: ACTIVE_COMPARATOR): Participants in this arm are administered 10 cc of chemotherapy, with 50mg doxorubicin and 10 mg of mitomycin-C via cTACE delivered in a lobar (whole liver) manner.
- superselective cTACE doxorubicin (Type: ACTIVE_COMPARATOR): Participants in this arm are administered 10 cc of chemotherapy, with 50mg doxorubicin and 10 mg of mitomycin-C via cTACE delivered in a super-selective (close to the tumor) manner.

Based on this trial design, predict the completion outcome and termination type (if applicable).